Question reference: S6W-26408
- Asked by: Jackie Baillie, MSP for Dumbarton, Scottish Labour
- Date lodged: 22 March 2024
-
Current status: Answered by Jenni Minto on 19 April 2024
Question
To ask the Scottish Government what discussions have taken place between NHS Scotland and Dr Hilary Cass regarding the prescription of puberty suppressing hormones to children and young people.
Answer
The final report from the NHS England-commissioned Independent Review of Gender Identity Services for Children and Young People (the ‘Cass Review’), chaired by Dr Hiliary Cass, was published on 10 April. The Cass Review did not review or consider clinical services as offered by Health Boards in Scotland.
However, both the Scottish Government and Scottish Health Boards had continued to proactively engage with the Cass Review as it progressed, to share information on improvement work in Scotland; shared learning; best practice; and to understand outputs of the review in England.
The Scottish Government welcomes the final report of the Cass Review, and we are now closely considering its findings at pace. Health Boards will also be considering the content of the report in the context of how this type of healthcare is delivered within Scotland.
On 18 April, in a joint statement, NHS Greater Glasgow and Clyde and NHS Lothian confirmed that both Boards have paused any new prescription of puberty-supressing hormones and cross-sex hormones for young people as a treatment option for gender dysphoria.
The small number of patients directly impacted by this change, and their families, were notified in advance of this statement. It is right that they were the first to hear about it, sensitively and from the services caring for them, before a public statement was made.